.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
QuintilesIMS
Cantor Fitzgerald
Citi
Colorcon
Cipla
US Army
Teva
UBS

Generated: December 16, 2017

DrugPatentWatch Database Preview

FLEXERIL Drug Profile

« Back to Dashboard

Which patents cover Flexeril, and what generic alternatives are available?

Flexeril is a drug marketed by Janssen Res And Dev and is included in one NDA.

The generic ingredient in FLEXERIL is cyclobenzaprine hydrochloride. There are fifteen drug master file entries for this compound. Seventy-seven suppliers are listed for this compound. Additional details are available on the cyclobenzaprine hydrochloride profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Res And DevFLEXERILcyclobenzaprine hydrochlorideTABLET;ORAL017821-001Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
Janssen Res And DevFLEXERILcyclobenzaprine hydrochlorideTABLET;ORAL017821-002Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: FLEXERIL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen Res And DevFLEXERILcyclobenzaprine hydrochlorideTABLET;ORAL017821-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Janssen Res And DevFLEXERILcyclobenzaprine hydrochlorideTABLET;ORAL017821-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Janssen Res And DevFLEXERILcyclobenzaprine hydrochlorideTABLET;ORAL017821-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Janssen Res And DevFLEXERILcyclobenzaprine hydrochlorideTABLET;ORAL017821-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Baxter
Teva
Cipla
McKinsey
McKesson
Medtronic
Federal Trade Commission
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot